Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment.
Luo R, Fu W, Shao J, Ma L, Shuai S, Xu Y, Jiang Z, Ye Z, Zheng L, Zheng L, Yu J, Zhang Y, Yin L, Tu L, Lv X, Li J, Liang G, Chen L.
Luo R, et al. Among authors: tu l.
Eur J Med Chem. 2023 May 5;253:115305. doi: 10.1016/j.ejmech.2023.115305. Epub 2023 Mar 24.
Eur J Med Chem. 2023.
PMID: 37023678